Lutetium oxodotreotide (¹⁷⁷Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.

ABSTRACT:

Background

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogenous group of tumors. Findings from the phase III NETTER-1 trial showed that treatment of unresectable/metastatic progressive gastrointestinal (GI) NETs with ¹⁷⁷Lu-Dotatate resulted in a significant improvement in progression-free survival (PFS) and overall survival (OS) compared with best supportive care (BSC) with high dose octreotide long-acting repeatable (LAR) 60 mg. A health economic analysis was performed using input data from clinical studies and data derived from an indirect comparison to determine the cost-effectiveness of ¹⁷⁷Lu-Dotatate in the treatment of GI-NETs and pancreatic NETs (P-NETs) in Scotland.

Methods

Cost-effectiveness analysis was performed fr

SUBMITTER: Smith-Palmer J 

PROVIDER: S-EPMC7786468 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature